Pluri Inc. (PLUR)
Price:
3.67 USD
( + 0.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
BioNTech SE
VALUE SCORE:
6
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
NEWS
Pluri Inc. (NASDAQ:PLUR) Sees Large Increase in Short Interest
defenseworld.net
2026-02-17 02:44:48Pluri Inc. (NASDAQ: PLUR - Get Free Report) was the target of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 22,147 shares, an increase of 22.7% from the January 15th total of 18,051 shares. Approximately 0.3% of the company's shares are sold short. Based
Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
globenewswire.com
2025-12-22 07:00:00HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. (“Remedy Cell”), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.
Pluri (NASDAQ:PLUR) Stock Price Down 12.7% – Here’s Why
defenseworld.net
2025-12-12 02:20:50Pluri Inc. (NASDAQ: PLUR - Get Free Report) shares dropped 12.7% during trading on Thursday. The stock traded as low as $3.04 and last traded at $3.09. Approximately 121,244 shares traded hands during trading, an increase of 136% from the average daily volume of 51,287 shares. The stock had previously closed at $3.54. Analyst Ratings
Plurilock Security Inc. (PLUR:CA) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-11-27 15:13:29Plurilock Security Inc. ( PLUR:CA ) Q3 2025 Earnings Call November 27, 2025 11:00 AM EST Company Participants Ian Paterson - CEO & Director Scott Meyers - CFO & Corporate Secretary Conference Call Participants Ryan Freemantle Presentation Ryan Freemantle Good morning, and thank you for joining us for Plurilock Securities conference call to discuss its financial results for the quarter ending September 30, 2025. I'm Ryan Freemantle from Sophic Capital, and we handle Plurilock's Investor Relations.
No data to display
Pluri Inc. (NASDAQ:PLUR) Sees Large Increase in Short Interest
defenseworld.net
2026-02-17 02:44:48Pluri Inc. (NASDAQ: PLUR - Get Free Report) was the target of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 22,147 shares, an increase of 22.7% from the January 15th total of 18,051 shares. Approximately 0.3% of the company's shares are sold short. Based
Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
globenewswire.com
2025-12-22 07:00:00HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. (“Remedy Cell”), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.
Pluri (NASDAQ:PLUR) Stock Price Down 12.7% – Here’s Why
defenseworld.net
2025-12-12 02:20:50Pluri Inc. (NASDAQ: PLUR - Get Free Report) shares dropped 12.7% during trading on Thursday. The stock traded as low as $3.04 and last traded at $3.09. Approximately 121,244 shares traded hands during trading, an increase of 136% from the average daily volume of 51,287 shares. The stock had previously closed at $3.54. Analyst Ratings
Plurilock Security Inc. (PLUR:CA) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-11-27 15:13:29Plurilock Security Inc. ( PLUR:CA ) Q3 2025 Earnings Call November 27, 2025 11:00 AM EST Company Participants Ian Paterson - CEO & Director Scott Meyers - CFO & Corporate Secretary Conference Call Participants Ryan Freemantle Presentation Ryan Freemantle Good morning, and thank you for joining us for Plurilock Securities conference call to discuss its financial results for the quarter ending September 30, 2025. I'm Ryan Freemantle from Sophic Capital, and we handle Plurilock's Investor Relations.